AVITA Medical (NASDAQ: RCEL) plummeted 26.55% in after-hours on August 7, 2025, trading at $3.95 after regular hours ended at $5.38.
The sharp decline was triggered by disappointing Q2 2025 results—revenue missed estimates ($18.42M vs. $22.61M expected), and the loss per share of $0.38 widened against forecasts.
Additionally, the company slashed its full-year revenue guidance from $100–106M to $67–81M, raising investor concerns about future growth.